||4R01CA166293-04 Interpret this number
||University Of California, San Diego
||Genomic, Clinical and Behavioral Signature of Long-Term Breast Cancer Survival
DESCRIPTION (provided by applicant): Breast cancer is a heterogeneous disease with substantial variability in relapse rates across clinical and molecular features of the tumor. Clinicopathologic prognostic models (e.g.,Adjuvant!) are widely used to guide therapy. Prognostic gene expression signatures are then used to help clarify treatment options for clinically intermediate risk patients. PAM50 is a validated "open source" gene expression signature which has recently been endorsed for informing treatment decisions. However, for 40% of breast cancer patients estimated risk, and hence treatment, remains uncertain. Improvement in prognostic models is an active area of research. Models that integrate genomic and clinicopathologic factors show large improvements in prognostic ability. Newer statistical methods (non-linear and time-varying effects, competing risks for comorbid conditions) have improved risk estimates among subgroups and increased accuracy for late relapse (>5 or 10 years after diagnosis). Combination of orthogonal gene expression signatures with microRNA's (miRNA's) promises to increase the proportion of subjects assigned to low and high-risk groups. However, clinical utility of newer models is limited because additional validation in large cohorts
with long-term follow-up is needed. Team: We have assembled unique resources to address these issues, including 1,723 well-annotated primary tumor samples from the WHEL cohort of community-dwelling early stage breast cancer survivors. WHEL participants have been actively followed for 15+ years, with regular assessment of comorbidities, body mass index, and physical activity. The team is comprised of leaders in breast cancer treatment and assay development, in genomics, in behavioral research, and in mathematical statistics and prognostic modeling. We aim to: 1. Assay PAM50, hypoxia gene signatures, and an 18 miRNA panel. Assays will be done at the Genome Institute, Washington Univ., St. Louis. We expect high-quality assays on ~1300 WHEL subjects. 2. Validate the PAM50/hypoxia clinco-genomic signatures, assess potential clinical benefit and identify weaknesses. We will compute risk estimates from published clinicopathologic models (Adjuvant), and genomic (PAM50, hypoxia, miRNA) signatures. We will validate models by comparing predicted and observed survival. Impact: The expected independent validation of the PAM50/hypoxia clinico-genomic signature will help translate its use into the clinic. Improvements for clinically intermediate-risk patientsare anticipated. 3, Develop a new prognostic model accounting for competing comorbidities, nonlinear and time- varying effects, and integrating novel genomic, and clinical factors. New models will integrate clinical and genomic features (i.e., PAM50, hypoxia signatures, miRNAs, comorbidities, obesity) and incorporate statistical refinements such as competing risk from non-cancer mortality and time-varying effects. Impact: We expect to further improve risk estimates for clinically intermediate risk and late relapse groups, and to quantify the expected clinical benefit which might result from these improved models.